Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape
Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape作者机构：Department of Adult GastroenterologyMcGill University Health CentreMontrealQC H3G 1A4Canada Department of MedicineMcGill University Health CentreMontrealQC H3G 1A4Canada 1^st Department of MedicineSemmelweis UniversityBudapest 1083Hungary
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2019年第25卷第30期
页 面：4158-4171页
核心收录：
基 金：Pfizer Roche Meso Scale Diagnostics, MSD Takeda Canada Shire
主 题：Inflammatory bowel disease Elderly Outcomes Glucocorticoids Biological therapy Surgery
摘 要：High-quality data remains scarce in terms of optimal management strategies in the elderly inflammatory bowel disease(IBD)***,available trials have been mostly retrospective,of small sample size,likely owing to underrepresentation of such a population in the major randomized controlled ***,in the last five years,there has been a steady increase in the number of published trials,helping clarify the estimated benefits and toxicity of the existing IBD *** the Everhov trial,prescription strategies were recorded over an average follow-up of 4.2 years.A minority of elderly IBD patients(1%-3%)were treated with biologics within the five years following diagnosis,whilst almost a quarter of these patients were receiving corticosteroid therapy at year five of follow-up,despite its multiple *** low use of biologic agents in real-life settings likely stems from limited data suggesting lower efficacy and higher *** minireview will aim to highlight current outcome measurements as it portends the elderly IBD patient,as well as summarize the available therapeutic strategies in view of a growing body of evidence.
维普期刊数据库